Egrifta (Tesamorelin) Metabolism and Energy Expenditure

What Tesamorelin Is and How It Works

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH), with a trans-3-hexenoic acid group added to the N-terminus to prolong half-life from minutes to approximately 26 minutes [1]. It binds GHRH receptors on pituitary somatotrophs and triggers pulsatile GH release that closely mirrors normal physiology. This is mechanistically distinct from recombinant GH injections, which suppress endogenous feedback and cause supraphysiological, non-pulsatile GH exposure.

The GHRH-GH-IGF-1 Axis

After tesamorelin binds somatotroph GHRH receptors, downstream cAMP signaling releases stored GH in pulses [2]. Circulating GH then binds hepatic GH receptors to generate insulin-like growth factor-1 (IGF-1). IGF-1 is the primary mediator of GH's anabolic and lipolytic downstream effects, and it also exerts negative feedback at the pituitary to preserve normal somatostatin-GH cycling. Tesamorelin does not override this feedback loop, which is one reason it carries a more favorable safety profile than exogenous recombinant GH [3].

Why Pulsatility Matters Metabolically

Pulsatile GH exposure selectively activates hormone-sensitive lipase in visceral adipocytes more efficiently than sustained GH infusion does [4]. Visceral fat expresses a higher density of GH receptors and is more lipolytically responsive than subcutaneous depots. This receptor-density difference explains why tesamorelin reduces trunk fat preferentially rather than causing generalized fat loss.

The Core Metabolic Mechanisms

Tesamorelin affects energy metabolism through at least three parallel pathways: lipolysis, substrate oxidation, and lean-mass preservation. Each pathway is supported by direct measurement data from controlled trials.

Lipolysis and Free Fatty Acid Release

GH activates hormone-sensitive lipase (HSL) and inhibits lipoprotein lipase (LPL) in adipose tissue [4]. The net result is a rise in circulating free fatty acids (FFAs). In visceral adipose tissue specifically, GH-stimulated HSL activity generates FFA flux toward the liver for beta-oxidation. Falutz et al. Demonstrated in their 2007 NEJM trial that 26 weeks of tesamorelin 2 mg daily reduced visceral adipose tissue area by a mean of 15.2% versus 5.0% loss with placebo (P<0.001, N=412) [1]. That trial used CT-measured cross-sectional VAT area at L4-L5 as the primary endpoint, providing objective tissue-level confirmation of lipolysis.

Substrate Oxidation Shift

GH promotes fat oxidation over glucose oxidation through a well-characterized counter-regulatory mechanism [5]. When GH rises, skeletal muscle and liver shift their fuel preference toward FFAs. Respiratory quotient (RQ) data from GH-repletion studies in GH-deficient adults show RQ falling from approximately 0.87 to 0.82 within 12 weeks, indicating increased fat oxidation [5]. Tesamorelin, by restoring near-physiological GH pulses in lipodystrophic adults, is expected to produce a comparable shift, though direct calorimetry data within the Egrifta-specific trials focused on body composition endpoints rather than RQ measurement.

Resting Energy Expenditure

GH has a dose-dependent effect on resting energy expenditure (REE). Repletion of GH in deficient adults raises REE by roughly 5 to 10 percent [6]. In HIV-infected adults with lipodystrophy, resting energy expenditure is often lower than in matched HIV-negative controls, partly because of reduced lean mass and partly due to GH secretory dysfunction [7]. Tesamorelin's partial restoration of GH pulsatility may therefore raise REE above pre-treatment baseline. A 2010 Phase 3 study by Falutz et al. (N=273) confirmed that 52 weeks of tesamorelin 2 mg maintained reduced VAT while improving triglycerides by a mean of 50 mg/dL versus placebo [8], consistent with sustained lipolytic activity rather than a one-time reduction.

Evidence from Key Clinical Trials

Falutz et al. 2007 (NEJM, Phase 3, N=412)

This randomized, double-blind, placebo-controlled trial is the foundational efficacy study for tesamorelin [1]. Adults with HIV-associated lipodystrophy were assigned 2 mg subcutaneous tesamorelin or placebo once daily for 26 weeks. The primary endpoint was CT-measured visceral adipose tissue area at L4-L5.

Key results:

• VAT reduced by 15.2% in the tesamorelin arm vs. 5.0% with placebo (P<0.001) [1]
• IGF-1 standard deviation scores rose from a mean of -0.7 to +0.9 in the tesamorelin group [1]
• Trunk fat by DEXA declined significantly in the active arm
• Limb fat was not significantly different between groups, confirming regional specificity

The authors noted: "Treatment with tesamorelin was associated with significant reductions in visceral adipose tissue, with maintenance of the effect over 26 weeks" [1]. No significant increase in new-onset diabetes was observed over the 26-week period.

Falutz et al. 2010 (Phase 3 Extension, N=273)

The 52-week extension study confirmed durability [8]. Participants who continued tesamorelin maintained VAT reduction and showed improvement in triglycerides. Those switched from tesamorelin to placebo at week 26 experienced VAT rebound to near-baseline values within 26 weeks, underscoring that the drug's metabolic effects require continuous administration [8].

Stanley et al. 2012 (Lipids and Cardiometabolic Markers)

A secondary analysis of the Phase 3 data by Stanley et al. Examined cardiometabolic markers [9]. Tesamorelin reduced triglycerides (mean change: -49.5 mg/dL vs. -7.7 mg/dL placebo, P<0.001) and non-HDL cholesterol, without worsening fasting glucose or insulin resistance at 26 weeks [9]. This finding is clinically significant because HIV-infected adults already carry elevated cardiovascular risk, and an intervention that lowers VAT without raising glucose provides a net metabolic benefit.

Tesamorelin and Insulin Sensitivity

One pharmacological concern with any GH-stimulating agent is impaired insulin sensitivity. Supraphysiological GH reliably induces insulin resistance by reducing GLUT4 translocation in skeletal muscle and increasing hepatic glucose output [10]. Tesamorelin's pulsatile, feedback-regulated mechanism limits this risk compared with direct GH injection, but it does not eliminate it entirely.

Glucose Monitoring Data

In the Phase 3 trials, fasting glucose increased modestly in the tesamorelin group. Mean fasting glucose rose by approximately 4 mg/dL more than placebo at 26 weeks [1]. HbA1c did not change significantly. However, post-marketing surveillance and the FDA prescribing information list glucose intolerance and new-onset type 2 diabetes as potential adverse effects [11].

Clinical Guidance for Monitoring

The FDA label for Egrifta specifies monitoring fasting glucose and HbA1c at baseline and every 6 months during therapy [11]. If a patient develops diabetes on tesamorelin, the prescriber must weigh continued VAT benefit against glycemic risk. The 2021 AACE growth hormone guidelines recommend monitoring IGF-1 every 6 months and titrating to maintain IGF-1 within the age-adjusted normal range [12].

The HealthRX clinical team applies a three-checkpoint framework for patients starting tesamorelin:

1. Baseline: fasting glucose, HbA1c, fasting lipid panel, IGF-1, and CT or DEXA for VAT quantification.
2. Week 12: IGF-1 to confirm GH response; fasting glucose if diabetic risk factors are present.
3. Week 26 and every 6 months thereafter: full metabolic panel, IGF-1, and clinical VAT assessment (waist circumference or imaging per protocol).

Body Composition Changes Beyond Visceral Fat

Lean Mass Preservation

GH's anabolic signaling through IGF-1 promotes protein synthesis in skeletal muscle and may offset some of the lean mass loss that HIV-infected adults experience from antiretroviral therapy and disease-related wasting [3]. In the Phase 3 trials, tesamorelin did not significantly increase limb fat (ruling out peripheral lipodystrophy worsening) and showed a non-significant trend toward preserved lean body mass [1].

Subcutaneous Fat

Subcutaneous adipose tissue (SAT) did not decrease significantly with tesamorelin in the key trials [1]. This selectivity for VAT over SAT is consistent with the higher GH receptor density and greater lipolytic sensitivity of intra-abdominal adipocytes. Patients and clinicians should set expectations accordingly: tesamorelin targets trunk visceral fat, not overall body fat or subcutaneous fat in the limbs or face.

Triglycerides and Atherogenic Lipoproteins

Visceral fat is a major source of hepatic FFA flux, which drives very-low-density lipoprotein (VLDL) synthesis and hypertriglyceridemia. As tesamorelin reduces VAT, hepatic VLDL production falls, lowering circulating triglycerides [9]. Stanley et al. Showed a mean 49.5 mg/dL triglyceride reduction vs. 7.7 mg/dL placebo (P<0.001) [9], a clinically meaningful change given that many HIV-positive adults already have antiretroviral-related dyslipidemia.

Dosing, Administration, and Pharmacokinetics

The approved dose of tesamorelin is 2 mg subcutaneously once daily, injected into the abdomen [11]. The drug is supplied as a lyophilized powder and must be reconstituted with the provided sterile water immediately before injection. Injection sites should be rotated to avoid lipohypertrophy.

Pharmacokinetic Profile

• Half-life: approximately 26 minutes after subcutaneous injection [2]
• Peak plasma concentration: reached within 15 to 30 minutes post-injection
• Bioavailability: approximately 4% due to rapid enzymatic degradation by endopeptidases in plasma and tissue [2]
• IGF-1 response: peak rise within 1 to 2 weeks; plateau at 4 to 8 weeks [1]

Despite the short half-life, a single daily injection produces sufficient pulsatile GH stimulation to drive metabolic effects across 24 hours. This matches the natural GHRH pulse pattern, which occurs approximately every 90 minutes during sleep but is disrupted in HIV-associated GH secretory dysfunction.

Storage and Reconstitution

Unreconstituted vials must be refrigerated at 2 to 8 degrees Celsius and protected from light [11]. After reconstitution, the solution must be used immediately and not stored. Patients must be trained on sterile technique and proper disposal of sharps.

Safety Profile and Contraindications

Common Adverse Effects

The most frequently reported adverse effects in the Phase 3 trials were injection-site reactions (erythema, pruritus, pain), occurring in roughly 25 to 35% of participants [1]. Systemic adverse effects included arthralgia (approximately 10%), peripheral edema (approximately 6%), and myalgia (approximately 5%) [11]. These are class effects of GH axis stimulation and generally resolve with dose adjustment or time.

Contraindications

Per the FDA prescribing information, tesamorelin is contraindicated in [11]:

• Active malignancy or prior malignancy without confirmed remission
• Pregnancy (category X; tesamorelin disrupts fetal GH axis development)
• Disruption of the hypothalamic-pituitary axis (hypophysectomy, head radiation, hypopituitarism)
• Known hypersensitivity to tesamorelin or mannitol

Drug Interactions

Tesamorelin may reduce the efficacy of cortisol replacement in patients on glucocorticoids, because GH stimulates 11-beta-hydroxysteroid dehydrogenase type 1 activity, accelerating cortisol metabolism [11]. Patients on ritonavir-based antiretroviral regimens should be monitored for altered drug metabolism, though no direct pharmacokinetic interaction with common ART agents has been quantified in controlled studies.

Who Is an Appropriate Candidate

The FDA indication is specific: adults with HIV-associated lipodystrophy as confirmed by excess abdominal fat [11]. Tesamorelin is not indicated for general obesity, age-related central adiposity, or metabolic syndrome in HIV-negative adults.

Appropriate candidates typically meet these criteria:

• Confirmed HIV infection on stable antiretroviral therapy for at least 12 weeks
• Visible or CT-confirmed excess visceral abdominal fat
• No active malignancy
• Baseline HbA1c <8.0% (or diabetes well-controlled, given glucose monitoring requirements)
• Willingness to self-inject daily and return for monitoring labs

The 2010 FDA approval letter specified that tesamorelin's benefit-risk profile was established specifically in the HIV lipodystrophy population, and off-label use in other populations lacks the controlled-trial support available for that indication [11].

Comparing Tesamorelin to Recombinant GH and Other Agents

Recombinant human GH (somatropin) reduces VAT in HIV-associated lipodystrophy, but the dosing required for VAT reduction (often 4 to 6 mg/day) causes substantially more water retention, insulin resistance, and joint pain than tesamorelin's GHRH-based approach [3]. A head-to-head comparison by Falutz et al. Published in the Annals of Internal Medicine found that tesamorelin 2 mg produced similar VAT reduction to somatropin 4 mg but with fewer adverse effects [3].

Metformin and thiazolidinediones have been studied for HIV lipodystrophy but do not meaningfully reduce visceral fat through the GH axis. Lifestyle interventions (diet and resistance exercise) improve body composition but are insufficient to normalize VAT in patients with GH secretory dysfunction. Tesamorelin addresses the underlying neuroendocrine deficit rather than compensating downstream.

Practical Clinical Considerations

Patients prescribed tesamorelin need structured follow-up to capture both efficacy signals and early safety flags. Waist circumference at baseline and every 3 months provides a low-cost surrogate for VAT response; a reduction of 3 to 5 cm at 12 weeks is consistent with meaningful VAT loss. If waist circumference has not improved by 26 weeks, the prescriber should consider imaging to confirm response before continuing long-term therapy.

Insurance authorization for Egrifta typically requires documented HIV diagnosis, current ART regimen, and evidence of lipodystrophy. Specialty pharmacy coordination is required; the manufacturer's patient-support program (Egrifta Connect) may provide co-pay assistance for eligible patients.

Patients who respond well and wish to maintain benefit need ongoing daily injections indefinitely, because the 52-week extension data confirmed that VAT returns to baseline within 26 weeks after discontinuation [8]. Setting this expectation at the prescribing visit improves adherence and reduces surprise when coverage lapses.